Wells Fargo & Company Candel Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 115 shares of CADL stock, worth $691. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115
Previous 113
1.77%
Holding current value
$691
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CADL
# of Institutions
22Shares Held
3.86MCall Options Held
0Put Options Held
0-
Northpond Ventures, LLC1.94MShares$11.6 Million8.58% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA812KShares$4.88 Million0.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA541KShares$3.25 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$875,6930.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX82.6KShares$496,3950.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $174M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...